Kanjinti 420 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26F9V49
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,659
Award facts
- Contract value 100% obligated
- $12,658.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,658.80 to AmerisourceBergen Drug Corp for the supply of Kanjinti 420 mg vials. This non-competitive, firm fixed-price delivery order was awarded on January 7, 2026, with an ultimate completion date of January 8, 2026, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.99 million through December 2031, which serves as the primary vehicle for delivering comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor, is well-positioned to fulfill this requirement given its extensive federal contracting history with the Defense Logistics Agency and its established role in the military medical supply chain. The contractor's parent organization, Cencora, Inc., maintains significant infrastructure and regulatory compliance to supply specialty medications, brand-name and generic drugs, and medical commodities across multiple therapeutic domains to military treatment facilities and other federal medical institutions. The delivery of Kanjinti (fam-trastuzumab deruxtecan-nxki), an oncology therapeutic, aligns with the contractor's demonstrated capability to supply specialized pharmaceutical products critical to military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F9V49?
SPE2DR26F9V49 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26F9V49 worth?
The government has obligated $12,659 on SPE2DR26F9V49.
Is contract SPE2DR26F9V49 an order under another contract?
Yes. SPE2DR26F9V49 is a delivery order under SPE2DR25D3103, an indefinite delivery contract.
Was contract SPE2DR26F9V49 competed?
The extent of competition for SPE2DR26F9V49 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award